My main research is focused in the study of rheumatoid arthritis (RA) and spondyloarthritis (SpA), both in the clinical and basic research field.
• Clinical research: I contribute in the assessment of the long-term efficacy-safety of biologic agents in patients with RA and SpA, through the organization of national and local registry studies. We study the burden of comorbidities, the biologic effects of biologic agents in RA and SpA patients, as well as the outcome of early and established RA.
• Basic research: We study immune responses pathways operable in RA development. Applying animal models and samples from patients with RA, we study the contribution of innate immunity components (NETosis, NLRP3 inflammasome), or adaptive immune system (PD1/PD-L1) and cellular contributors (pDCs, DCs) in the inflammatory responses in RA.
• Translational research: We investigate for biomarkers of clinical responses of biologic therapies in RA (rituximab, abatacept, tofacitinib) as well as for biomarkers of the outcome of early RA.

Publications (Web of Science, January 2025)
Total : 143
Total citations: 5794
Average citations: 40.5
h-index: 42

1. Dantrolene is an HDL-associated paraoxonase-1 activator with immunosuppressive and atheroprotective properties. Dedemadi AG, Sevdali E, Georgiadou D, Valanti EK, Neofotistou-Themeli E, Chanis T, Goutakoli P, Thymiakou E, Drakos E, Christopoulou G, Bournazos S, Constantoulakis P, Verginis P, Kardassis D, Stratikos E, Sidiropoulos P, Chroni A. Biochim Biophys Acta Mol Cell Biol Lipids. 2025 Jan 20;1870(2):159596. doi: 10.1016/j.bbalip.2025.159596. Online ahead of print. PMID: 39842506

2. Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study. Katechis S, Pitsigavdaki S, Nikoloudaki M, Silvagni E, Repa A, Marangoni A, Flouri I, Avgoustidis N, Parperis K, Govoni M, Sidiropoulos P, Boumpas DT, Fanouriakis A, Bertsias G, Bortoluzzi A. RMD Open. 2025 Jan 6;11(1):e005118. doi: 10.1136/rmdopen-2024-005118. PMID: 39762120 Free PMC article.

3. Performance of Lung Ultrasound as a Screening Tool for Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multicenter Study. Otaola M, Vasarmidi E, Ottaviani S, Gutierrez M, Dalpiaz MS, Gaser A, Juge PA, Bertolazzi C, Avgoustidis N, Skiadas C, Della Maggiora M, Orausclio P, Quintana-Rodriguez A, Debray MP, Cepas BP, Schneeberger E, Sidiropoulos P, Schenone NL, Rosemffet M, Marciano S, Antoniou K. Chest. 2024 Dec 13:S0012-3692(24)05622-8. doi: 10.1016/j.chest.2024.11.038. Online ahead of print. PMID: 39675519

4. Low-Grade Activation of the Extrinsic Coagulation Pathway in Patients with Ulcerative Colitis. Drygiannakis I, Valatas V, Filidou E, Tzenaki N, Archontoulaki E, Dovrolis N, Kandilogiannakis L, Kefalogiannis G, Sidiropoulos P, Kolios G, Koutroubakis IE. Dig Dis Sci. 2024 Oct;69(10):3773-3785. doi: 10.1007/s10620-024-08640-1. Epub 2024 Sep 25. PMID: 39322807

5. Attainment of EULAR/ERA-EDTA targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study. Pappa M, Kosmetatou M, Pieta A, Nikoloudaki M, Liapis NM, Tsalapaki C, Chalkia A, Argyriou E, Dimitroulas T, Cheila M, Demirtzoglou G, Papagoras C, Goules A, Katsiari C, Vassilopoulos D, Sidiropoulos P, Boki KA, Sfikakis PP, Liapis G, Gakiopoulou H, Voulgari PV, Boumpas DT, Bertsias G, Tektonidou MG, Fanouriakis A. RMD Open. 2024 Sep 18;10(3):e004437. doi: 10.1136/rmdopen-2024-004437. PMID: 39299738 Free PMC article.

6. Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment. Dedemadi AG, Gkolfinopoulou C, Nikoleri D, Nikoloudaki M, Ruhanen H, Holopainen M, Kakela R, Christopoulou G, Bournazos S, Constantoulakis P, Sidiropoulos P, Bertsias G, Chroni A. Rheumatology (Oxford). 2024 Mar 21:keae192. doi: 10.1093/rheumatology/keae192. Online ahead of print. PMID: 38514392

7. Comorbidities Burden and Implementation of the Treat-to-Target Strategy in Predicting Real-World Patient Outcomes in Spondyloarthritides. Flouri ID, Repa A, Avgoustidis N, Pitsigavdaki S, Pateromichelaki K, Marolachaki E, Terizaki M, Nikoloudaki M, Eskitzis A, Kalogiannaki E, Bertsias G, Sidiropoulos P. Mediterr J Rheumatol. 2023 Jul 31;34(4):581-587. doi: 10.31138/mjr.310723.cba. eCollection 2023 Dec. PMID: 38282943 Free PMC article.

8. Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with ‘difficult to treat’ rheumatoid arthritis. Bertsias A, Flouri ID, Repa A, Avgoustidis N, Kalogiannaki E, Pitsigavdaki S, Bertsias G, Sidiropoulos P. RMD Open. 2024 Jan 19;10(1):e003808. doi: 10.1136/rmdopen-2023-003808. PMID: 38242549

9. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, Flouri I, Avgoustidis N, Parperis K, Fanouriakis A, Govoni M, Sidiropoulos P, Boumpas DT, Bortoluzzi A, Bertsias G. Ann Rheum Dis. 2024 Mar 12;83(4):464-474. doi: 10.1136/ard-2023-224919. PMID: 38233103

10. A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients. Goutakoli P, Papadaki G, Repa A, Avgoustidis N, Kalogiannaki E, Flouri I, Bertsias A, Zoidakis J, Samiotaki M, Bertsias G, Semitekolou M, Verginis P, Sidiropoulos P. Cells. 2023 Dec 9;12(24):2808. doi: 10.3390/cells12242808. PMID: 38132128 Free PMC article.

11. The SYSCID map: a graphical and computational resource of molecular mechanisms across rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease. Acencio ML, Ostaszewski M, Mazein A, Rosenstiel P, Aden K, Mishra N, Andersen V, Sidiropoulos P, Banos A, Filia A, Rahmouni S, Finckh A, Gu W, Schneider R, Satagopam V. Front Immunol. 2023 Nov 1;14:1257321. doi: 10.3389/fimmu.2023.1257321. eCollection 2023. PMID: 38022524 Free PMC article.

12. Progressive Multifocal Leukoencephalopathy in Systemic Lupus Erythematosus: A Consequence of Patient-Intrinsic or -Extrinsic Factors? Emmanouilidou E, Kosmara D, Papadaki E, Mastorodemos V, Constantoulakis P, Repa A, Christopoulou G, Kalpadakis C, Avgoustidis N, Thomas K, Boumpas D, Sidiropoulos P, Bertsias G. J Clin Med. 2023 Nov 6;12(21):6945. doi: 10.3390/jcm12216945.vPMID: 37959410 Free PMC article.

13. Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study. Flouri I, Goutakoli P, Repa A, Bertsias A, Avgoustidis N, Eskitzis A, Pitsigavdaki S, Kalogiannaki E, Terizaki M, Bertsias G, Sidiropoulos P. Rheumatol Int. 2023 Oct 10. doi: 10.1007/s00296-023-05455-7. Online ahead of print. PMID: 37815625

14. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study. Athanassiou P, Psaltis D, Georgiadis A, Katsifis G, Theodoridou A, Gazi S, Sidiropoulos P, Tektonidou MG, Bounas A, Kandyli A, Vounotrypidis P, Sakellariou GT, Vassilopoulos D, Huang Z, Petrikkou E, Boumpas D. Rheumatol Int. 2023 Oct;43(10):1871-1883. doi: 10.1007/s00296-023-05376-5. Epub 2023 Jul 5. PMID: 37402886

15. Altered hippocampal connectivity dynamics predicts memory performance in neuropsychiatric lupus: a resting-state fMRI study using cross-recurrence quantification analysis. Pentari A, Simos N, Tzagarakis G, Kagialis A, Bertsias G, Kavroulakis E, Gratsia E, Sidiropoulos P, Boumpas DT, Papadaki E. Lupus Sci Med. 2023 Jul;10(2):e000920. doi: 10.1136/lupus-2023-000920. PMID: 37400223 Free PMC article.

16. Cost of Illness, Quality of Life, and Work Productivity in Axial Spondyloarthritis Patients Receiving Biological Treatments in Greece. Kougkas N, Mylonas C, Avgoustidis N, Flouri I, Sidiropoulos P, Dimitroulas T, Garyfallos A. Mediterr J Rheumatol. 2023 Mar 31;34(1):37-43. doi: 10.31138/mjr.34.1.37. eCollection 2023 Mar. PMID: 37223606 Free PMC article.

17. Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study. Sfikakis PP, Vassilopoulos D, Katsifis G, Vosvotekas G, Dimitroulas T, Sidiropoulos P, Vounotrypidis P, Bogdanos DP, Georgountzos AΙ, Bounas AG, Georgiou P, Gazi S, Kataxaki E, Liossis SN, Theodorou E, Papagoras C, Theotikos E, Vlachoyiannopoulos P, Voulgari PV, Kekki A, Antonakopoulos N, Boumpas DT. Rheumatol Int. 2023 May;43(5):889-902. doi: 10.1007/s00296-022-05269-z. Epub 2023 Mar 1. PMID: 36856816 Free PMC article.

18. Clinical features and outcomes of patients with myositis associated-interstitial lung disease. Karampitsakos T, Tzilas V, Papaioannou O, Chrysikos S, Vasarmidi E, Juge PA, Vizirianaki S, Bibaki E, Reppa A, Sidiropoulos P, Katsaras M, Sotiropoulou V, Tsiri P, Koulousousa E, Theochari E, Tsirikos G, Christopoulos I, Malakounidou E, Zarkadi E, Sampsonas F, Hillas G, Karageorgas T, Daoussis D, Kalogeropoulou C, Dimakou K, Tzanakis N, Borie R, Dieudé P, Antoniou K, Crestani B, Bouros D, Tzouvelekis A. Front Med (Lausanne). 2023 Jan 9;9:1096203. doi: 10.3389/fmed.2022.1096203. eCollection 2022. PMID: 36698813 Free PMC article.

19. Patterns and factors associated with pneumococcal vaccination in a prospective cohort of 1,697 patients with rheumatoid arthritis. Thomas K, Lazarini A, Kaltsonoudis E, Voulgari PV, Drosos AA, Repa A, Sali AMI, Sidiropoulos P, Tsatsani P, Gazi S, Fragkiadaki K, Tektonidou MG, Sfikakis PP, Katsimbri P, Boumpas D, Argyriou E, Boki KA, Karagianni K, Katsiari C, Evangelatos G, Iliopoulos A, Grika EP, Vlachoyiannopoulos PG, Dimitroulas T, Garyfallos A, Melissaropoulos K, Georgiou P, Georganas C, Vounotrypidis P, Ntelis K, Areti M, Kitas GD, Vassilopoulos D. Front Med (Lausanne). 2023 Jan 9;9:1039464. doi: 10.3389/fmed.2022.1039464. eCollection 2022. PMID: 36698802 Free PMC article.

20. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study. Nikoloudaki M, Nikolopoulos D, Koutsoviti S, Flouri I, Kapsala N, Repa A, Katsimbri P, Theotikos E, Pitsigavdaki S, Pateromichelaki K, Bertsias A, Elezoglou A, Sidiropoulos P, Fanouriakis A, Boumpas D, Bertsias G. Front Immunol. 2023 Jan 4;13:1074044. doi: 10.3389/fimmu.2022.1074044. eCollection 2022. PMID: 36685524 Free PMC article.

21. IL-6 Signaling Attenuates TNF-α Production by Plasmacytoid Dendritic Cells in Rheumatoid Arthritis. Papadaki G, Goutakoli P, Tiniakou I, Grün JR, Grützkau A, Pavlopoulos GA, Iliopoulos I, Bertsias G, Boumpas D, Ospelt C, Reizis B, Sidiropoulos P, Verginis P. J Immunol. 2022 Nov 15;209(10):1906-1917. doi: 10.4049/jimmunol.2100882. PMID: 36426957

22. Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease. Mishra N, Aden K, Blase JI, Baran N, Bordoni D, Tran F, Conrad C, Avalos D, Jaeckel C, Scherer M, Sørensen SB, Overgaard SH, Schulte B, Nikolaus S, Rey G, Gasparoni G, Lyons PA, Schultze JL, Walter J, Andersen V; SYSCID Consortium; Dermitzakis ET, Schreiber S, Rosenstiel P. Genome Med. 2022 Sep 24;14(1):110. doi: 10.1186/s13073-022-01112-z. PMID: 36153599 Free PMC article.

23. Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients. Sénard T, Flouri I, Vučković F, Papadaki G, Goutakoli P, Banos A, Pučić-Baković M, Pezer M, Bertsias G, Lauc G, Sidiropoulos P. Arthritis Res Ther. 2022 Aug 25;24(1):206. doi: 10.1186/s13075-022-02897-5. PMID: 36008868 Free PMC article.

24. Persistence of Depression and Anxiety despite Short-Term Disease Activity Improvement in Patients with Systemic Lupus Erythematosus: A Single-Centre, Prospective Study. Nikoloudaki M, Repa A, Pitsigavdaki S, Molla Ismail Sali A, Sidiropoulos P, Lionis C, Bertsias G. J Clin Med. 2022 Jul 25;11(15):4316. doi: 10.3390/jcm11154316. PMID: 35893407 Free PMC article.

25. Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study. Bertsias A, Avgoustidis N, Papalopoulos I, Repa A, Kougkas N, Kalogiannaki E, Bertsias G, Flouri I, Sidiropoulos P. Arthritis Res Ther. 2022 Jun 2;24(1):132. doi: 10.1186/s13075-022-02826-6. PMID: 35655317 Free PMC article.

26. Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in Rheumatoid Arthritis Patients in Greece: Analysis of the Greek Cohort of SENSE study. Sidiropoulos P, Bounas A, Galanopoulos N, Vosvotekas G, Koukli EM, Georgiou P, Marketos N, Antachopoulou T, Kyriakakis A, Koronaiou M. Mediterr J Rheumatol. 2022 Mar 31;33(1):14-34. doi: 10.31138/mjr.33.1.14. eCollection 2022 Mar. PMID: 35611113 Free PMC article.

27. Deciphering the Molecular Mechanism of Flares in Patients with Systemic Lupus Erythematosus through Single-Cell Transcriptome Analysis of the Peripheral Blood. Papanikolaou S, Kosmara D, Stathopoulou C, Sidiropoulos P, Konstantopoulos D, Bertsias G. Mediterr J Rheumatol. 2022 Mar 31;33(1):94-98. doi: 10.31138/mjr.33.1.94. eCollection 2022 Mar. PMID: 35611101 Free PMC article.

28. Converging evidence of impaired brain function in systemic lupus erythematosus: changes in perfusion dynamics and intrinsic functional connectivity. Papadaki E, Simos NJ, Kavroulakis E, Bertsias G, Antypa D, Fanouriakis A, Maris T, Sidiropoulos P, Boumpas DT. Neuroradiology. 2022 Aug;64(8):1593-1604. doi: 10.1007/s00234-022-02924-x. Epub 2022 Mar 6. PMID: 35249129

29. The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study. Psaltis D, Settas L, Georgiadis A, Koukli E, Bounas A, Livieratos A, Petrikkou E, Kalogiannaki H, Repa A, Vassilopoulos D, Sidiropoulos P. Rheumatol Int. 2022 Apr;42(4):639-650. doi: 10.1007/s00296-021-05073-1. Epub 2022 Jan 29. PMID: 35091757

30. Remission or low disease activity at pregnancy onset are linked to improved foetal outcomes in women with systemic lupus erythematosus: results from a prospective observational study. Ntali S, Nikolopoulos D, Pantazi L, Emmanouilidou E, Papagoras C, Fanouriakis A, Dimopoulou D, Kallitsakis I, Boki K, Dania V, Sidiropoulos PI, Boumpas DT, Bertsias G. Clin Exp Rheumatol. 2022 Sep;40(9):1769-1778. doi: 10.55563/clinexprheumatol/g4rby6. Epub 2022 Jan 5. PMID: 35084312 Free article.

31. Screening for cognitive impairment in systemic lupus erythematosus: Application of the Montreal Cognitive Assessment (MoCA) in a Greek patient sample. Papastefanakis E, Dimitraki G, Ktistaki G, Fanouriakis A, Karamaouna P, Bardos A, Kallitsakis I, Adamichou C, Gergianaki I, Repa A, Bertsias G, Sidiropoulos P, Karademas E, Simos P. Lupus. 2021 Dec;30(14):2237-2247. doi: 10.1177/09612033211061062. Epub 2021 Dec 3. PMID: 34861804

32. NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-α production in patients with SLE. Georgakis S, Gkirtzimanaki K, Papadaki G, Gakiopoulou H, Drakos E, Eloranta ML, Makridakis M, Kontostathi G, Zoidakis J, Baira E, Rönnblom L, Boumpas DT, Sidiropoulos P, Verginis P, Bertsias G. JCI Insight. 2021 Nov 8;6(21):e147671. doi: 10.1172/jci.insight.147671. PMID: 34554930 Free PMC article.

33. MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression. Juge PA, Solomon JJ, van Moorsel CHM, Garofoli R, Lee JS, Louis-Sydney F, Rojas-Serrano J, González-Pérez MI, Mejia M, Buendia-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou KM, Sidiropoulos P, Trachalaki A, van der Vis JJ, Jamnitski A, Grutters JC, Kannengiesser C, Borie R, Kawano-Dourado L, Wemeau-Stervinou L, Flipo RM, Nunes H, Uzunhan Y, Valeyre D, Saidenberg-Kermanac’h N, Boissier MC, Richez C, Schaeverbeke T, Doyle T, Wolters PJ, Debray MP, Boileau C, Porcher R, Schwartz DA, Crestani B, Dieudé P. Semin Arthritis Rheum. 2021 Oct;51(5):996-1004. doi: 10.1016/j.semarthrit.2021.07.002. Epub 2021 Jul 10. PMID: 34411838

34. Rituximab for refractory eosinophilic fasciitis: a case series with long-term follow-up and literature review. Kougkas N, Bertsias G, Papalopoulos I, Repa A, Sidiropoulos P, Avgoustidis N. Rheumatol Int. 2021 Oct;41(10):1833-1837. doi: 10.1007/s00296-021-04887-3. Epub 2021 May 19. PMID: 34009397

35. Anxiety and depression severity in neuropsychiatric SLE are associated with perfusion and functional connectivity changes of the frontolimbic neural circuit: a resting-state f(unctional) MRI study. Antypa D, Simos NJ, Kavroulakis E, Bertsias G, Fanouriakis A, Sidiropoulos P, Boumpas D, Papadaki E. Lupus Sci Med. 2021 Apr;8(1):e000473. doi: 10.1136/lupus-2020-000473. PMID: 33927003 Free PMC article.

36. High Comorbidity Burden in Patients with SLE: Data from the Community-Based Lupus Registry of Crete. Gergianaki I, Garantziotis P, Adamichou C, Saridakis I, Spyrou G, Sidiropoulos P, Bertsias G. J Clin Med. 2021 Mar 2;10(5):998. doi: 10.3390/jcm10050998. PMID: 33801229 Free PMC article.

37. Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study. Taylor PC, Ancuta C, Nagy O, de la Vega MC, Gordeev A, Janková R, Kalyoncu U, Lagunes-Galindo I, Morović-Vergles J, de Souza MPGUES, Rojkovich B, Sidiropoulos P, Kawakami A. Patient Prefer Adherence. 2021 Feb 17;15:359-373. doi: 10.2147/PPA.S289692. eCollection 2021. PMID: 33633444 Free PMC article.

38. Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. Adamichou C, Genitsaridi I, Nikolopoulos D, Nikoloudaki M, Repa A, Bortoluzzi A, Fanouriakis A, Sidiropoulos P, Boumpas DT, Bertsias GK. Ann Rheum Dis. 2021 Jun;80(6):758-766. doi: 10.1136/annrheumdis-2020-219069. Epub 2021 Feb 10. PMID: 33568388 Free PMC article.

39. Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. Thomas K, Lazarini A, Kaltsonoudis E, Voulgari PV, Drosos AA, Repa A, Sali AMI, Sidiropoulos P, Tsatsani P, Gazi S, Evangelia A, Boki KA, Katsimbri P, Boumpas D, Fragkiadaki K, Tektonidou MG, Sfikakis PP, Karagianni K, Sakkas LI, Grika EP, Vlachoyiannopoulos PG, Evangelatos G, Iliopoulos A, Dimitroulas T, Garyfallos A, Melissaropoulos K, Georgiou P, Areti M, Georganas C, Vounotrypidis P, Georgiopoulos G, Kitas GD, Vassilopoulos D. Rheumatology (Oxford). 2021 May 14;60(5):2223-2230. doi: 10.1093/rheumatology/keaa557. PMID: 33295627

40. Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. Thomas K, Lazarini A, Kaltsonoudis E, Drosos A, Papalopoulos I, Sidiropoulos P, Tsatsani P, Gazi S, Pantazi L, Boki KA, Katsimbri P, Boumpas D, Fragkiadaki K, Tektonidou M, Sfikakis PP, Karagianni K, Sakkas LI, Grika EP, Vlachoyiannopoulos PG, Evangelatos G, Iliopoulos A, Dimitroulas T, Garyfallos A, Melissaropoulos K, Georgiou P, Areti M, Georganas C, Vounotrypidis P, Kitas GD, Vassilopoulos D. Ther Adv Musculoskelet Dis. 2020 Sep 28;12:1759720X20937132. doi: 10.1177/1759720X20937132. eCollection 2020. PMID: 33062066 Free PMC article.

41. Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group. Genitsaridi I, Flouri I, Plexousakis D, Marias K, Boki K, Skopouli F, Drosos A, Bertsias G, Boumpas D, Sidiropoulos P. Arthritis Res Ther. 2020 Sep 29;22(1):226. doi: 10.1186/s13075-020-02313-w. PMID: 32993800 Free PMC article.

42. EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. Meisters R, Putrik P, Ramiro S, Hifinger M, Keszei AP, van Eijk-Hustings Y, Woolf AD, Smolen JS, Stamm TA, Stoffer-Marx M, Uhlig T, Moe RH, de Wit M, Tafaj A, Mukuchyan V, Studenic P, Verschueren P, Shumnalieva R, Charalambous P, Vencovský J, Varvouni M, Kull M, Puolakka K, Gossec L, Gobejishvili N, Detert J, Sidiropoulos P, Péntek M, Kane D, Scirè CA, Arad U, Andersone D, van de Laar M, van der Helm-van Mil A, Głuszko P, Cunha-Miranda L, Berghea F, Damjanov NS, Tomšič M, Carmona L, Turesson C, Ciurea A, Shukurova S, Inanc N, Verstappen SM, Boonen A; Working group. Ann Rheum Dis. 2020 Nov;79(11):1423-1431. doi: 10.1136/annrheumdis-2020-217520. Epub 2020 Sep 1. PMID: 32873554

43. Updated Greek Rheumatology Society Guidelines for the Management of Rheumatoid Arthritis. Vassilopoulos D, Aslanidis S, Boumpas D, Kitas G, Nikas SN, Patrikos D, Sfikakis PP, Sidiropoulos P. Mediterr J Rheumatol. 2020 Jun 11;31(Suppl 1):163-171. doi: 10.31138/mjr.31.1.163. eCollection 2020 Jun. PMID: 32676575 Free PMC article. No abstract available.

44. Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece. Sidiropoulos P, Bounas A, Athanassiou P, Koutsianas C, Petrikkou E, Kaltsonoudis E, Drosos A, Vassilopoulos D. Clin Rheumatol. 2020 Dec;39(12):3643-3652. doi: 10.1007/s10067-020-05171-8. Epub 2020 May 26. PMID: 32458235
45. Thomas ML, Shaddick G, Charlton R, Cavill C, Holland R, Iannone F, Lapadula G, Lopriore S, Závada J, Uher M, Pavelka K, Szczukova L, Sidiropoulos P, Flouri I, Drosos A, Möller B, Nissen MJ, Müller RB, Scherer A, McHugh N* & Nightingale A*. Tumour Necrosis Factor Inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: combined analysis of European biologics databases. J Rheumatol. 2021 Jan 1;48(1):48-57. doi: 10.3899/jrheum.190815.

46. Panopoulos S, Chatzidionysiou A, Tektonidou M, Mpournia VK, Liossis NS, Dimitroulas T, Sakkas L, Boumpas DT, Voulgari P, Daoussis D, Thomas K, Georgiopoulos G, Vosvotekas G, Garyfallos A, Sidiropoulos P, Bertsias G, Vassilopoulos D, Sfikakis P. Treatment modalities and drug survival in a systemic sclerosis real-life patient. Arthritis Res Ther. 2020 Mar 23;22(1):56. doi: 10.1186/s13075-020-2140-3.

47. Papadaki E, Kavroulakis E, Bertsias G, Fanouriakis A, Karageorgou D, Sidiropoulos P, Papastefanakis E, Boumpas DT, Simos P. Regional cerebral perfusion correlates with anxiety in neuropsychiatric SLE: evidence for a mechanism distinct from depression. Lupus. 2019. Dec;28(14):1678-1689. doi: 10.1177/0961203319887793. Epub 2019 Nov 13. PMID: 31718491

48. Adamichou C, Nikolopoulos D, Genitsaridi I, Bortoluzzi A, Fanouriakis A, Papastefanakis E, Kalogiannaki E, Gergianaki I, Sidiropoulos P, Boumpas DT, Bertsias GK. In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Ann Rheum Dis. 2019 Nov 8. pii: annrheumdis-2019-216155. doi: 10.1136/annrheumdis-2019-216155. [Epub ahead of print] PMID: 31704720

49. Putrik P, Ramiro S, Guillemin F, Péntek M, Sivera F, Sokka T, de Wit M, Woolf AD, Zink A, Andersone D, Berghea F, Butrimiene I, Brouwer S, Cassar K, Charalambous P, Caporali R, Deseatnicova E, Damjanov NS, Finckh A, FitzGerald O, Gröndal G, Gobejishjvili N, Gluszko P, Hirsch M, Jovanovic I, Vencovský J, Janssens X, Keszei AP, Kovarova M, Kull M, Cunha Miranda L, Mayer M, Misevska-Percinkova S, Inanc N, Nadashkevich O, Petersson IF, Puolakka K, Rojkovich B, Radner H, Szabados F, Slobodin G, Shirinsky I, Soroka N, Sidiropoulos P, Shumnalieva R, Sokolovic S, Shukurova S, Tafaj A, Tomšič M, Uhlig T, Verstappen SMM, Boonen A. Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. Ann Rheum Dis. 2019 Nov;78(11):1472-1479. doi: 10.1136/annrheumdis-2019-215294. Epub 2019 Aug 19. PMID: 31427438

50. Panousis NI, Bertsias GK, Ongen H, Gergianaki I, Tektonidou MG, Trachana M, Romano-Palumbo L, Bielser D, Howald C, Pamfil C, Fanouriakis A, Kosmara D, Repa A, Sidiropoulos P, Dermitzakis ET, Boumpas DT. Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. Ann Rheum Dis. 2019 Aug;78(8):1079-1089. doi: 10.1136/annrheumdis-2018-214379. Epub 2019 Jun 5. PMID: 31167757.

51. Boumpas DT, Sidiropoulos P, Settas L, Szczypa P, Tsekouras V, Hernandez Daly AC. Health outcomes and unmet needs in patients with long-standing rheumatoid arthritis attending tertiary care in Greece: a cohort study. Health Qual Life Outcomes. 2019 Apr 29;17(1):73. doi: 10.1186/s12955-019-1127-8. PMID: 31036012

52. Gergianaki I, Fanouriakis A, Adamichou C, Spyrou G, Mihalopoulos N, Kazadzis S, Chatzi L, Sidiropoulos P, Boumpas DT, Bertsias G. Is systemic lupus erythematosus different in urban versus rural living environment? Data from the Cretan Lupus Epidemiology and Surveillance Registry. Lupus. 2019 Jan;28(1):104-113. doi: 10.1177/ 0961203318816820. Epub 2018 Dec 6. PMID: 30522399.

53. Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, Tsalapaki C, Pantazi L, Konsta S, Mavragani CP, Dimopoulou D, Ntali S, Katsikas G, Boki KA, Vassilopoulos D, Konstantopoulou P, Liossis SN, Elezoglou A, Tektonidou M, Sidiropoulos P, Erden A, Sfikakis PP, Bertsias G, Boumpas DT. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. Semin Arthritis Rheum. 2018 Dec;48(3):467-474. doi: 10.1016/j.semarthrit.2018.02.014. Epub 2018 Feb 23. PMID: 29555348.

54. Gkirtzimanaki K, Kabrani E, Nikoleri D, Polyzos A, Blanas A, Sidiropoulos P, Makrigiannakis A, Bertsias G, Boumpas DT, Verginis P. IFNα Impairs Autophagic Degradation of mtDNA Promoting Autoreactivity of SLE Monocytes in a STING-Dependent Fashion. Cell Rep. 2018 Oct 23;25(4):921-933.e5. doi: 10.1016/j.celrep. 2018.09.001. PMID: 30355498.

55. Fanouriakis A, Papalopoulos I, Gergianaki I, Spyrou G, Erden A, Rapsomaniki P, Terizaki M, Avgoustidis N, Repa A, Kougkas N, Bertsias G, Boumpas DT, Sidiropoulos PI. In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study. Clin Exp Rheumatol. 2018 Sep-Oct;36(5):806-813. Epub 2018 Feb 28. PMID: 29533750

56. Kougkas N, Fanouriakis A, Papalopoulos I, Bertsias G, Avgoustidis N, Repa A, Sidiropoulos P. Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up. Rheumatology (Oxford). 2018 Aug 1;57(8):1494-1495. doi: 10.1093/rheumatology/key077. PMID: 30060102

57. Karademas EC, Dimitraki G, Papastefanakis E, Ktistaki G, Repa A, Gergianaki I, Bertsias G, Sidiropoulos P, Mastorodemos V, Simos P. Emotion regulation contributes to the well-being of patients with autoimmune diseases through illness-related emotions: A prospective study. J Health Psychol. 2018 Jul 1:1359105318787010. doi:10.1177/ 1359105318787010. [Epub ahead of print] PMID: 29992828

58. Flouri ID, Markatseli TE, Boki KA, Papadopoulos I, Skopouli FN, Voulgari PV, Settas L, Zisopoulos D, Iliopoulos A, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence. J Rheumatol. 2018 Jun;45(6):785-794. doi: 10.3899/jrheum.170477. Epub 2018 Apr 1. PMID: 29606666.

59. Karademas EC, Dimitraki G, Papastefanakis E, Ktistaki G, Repa A, Gergianaki I, Bertsias G, Sidiropoulos P, Simos P. Adaptation to inflammatory rheumatic disease: Do illness representations predict patients’ physical functioning over time? A complex relationship. J Behav Med. 2018 Apr;41(2):232-242. doi: 10.1007/s10865-017-9889-0. Epub 2017 Sep 21. PMID: 28936564.

60. Papadaki E, Fanouriakis A, Kavroulakis E, Karageorgou D, Sidiropoulos P, Bertsias G, Simos P, Boumpas DT. Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus. Ann Rheum Dis. 2018 Mar;77(3):441-448. doi: 10.1136/ annrheumdis-2017-212285. Epub 2017 Dec 19. PMID: 29259047. (14)

61. Thomas K, Flouri I, Repa A, Fragiadaki K, Sfikakis PP, Koutsianas C, Kaltsonoudis E, Voulgari PV, Drosos AA, Petrikkou E, Sidiropoulos P, Vassilopoulos D. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients. Clin Exp Rheumatol. 2018 Mar-Apr;36(2):254-262. Epub 2017 Nov 9. PMID: 29148406.

62. Papalopoulos I, Fanouriakis A, Kougkas N, Flouri I, Sourvinos G, Bertsias G, Repa A, Avgoustidis N, Sidiropoulos P. Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study. Clin Exp Rheumatol. 2018 Jan-Feb;36(1):102-109. Epub 2017 Aug 28. PMID: 28850029.

63. Gergianaki I, Fanouriakis A, Repa A, Tzanakakis M, Adamichou C, Pompieri A, Spirou G, Bertsias A, Kabouraki E, Tzanakis I, Chatzi L, Sidiropoulos P, Boumpas DT, Bertsias GK. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Ann Rheum Dis. 2017 Dec;76(12):1992-2000. doi: 10.1136/annrheumdis-2017-211206. Epub 2017 Aug 5. PMID: 28780511.

64. Zervou MI, Dimopoulou DG, Eliopoulos E, Trachana M, Pratsidou-Gkertsi P, Andreou A, Sidiropoulos P, Spandidos DA, Garyfallos A, Goulielmos GN. Τhe genetics of juvenile idiopathic arthritis: Searching for new susceptibility loci. Mol Med Rep. 2017 Dec;16(6):8793-8798. doi: 10.3892/mmr.2017.7733. Epub 2017 Oct 5. PMID: 28990043

65. Karademas EC, Ktistaki G, Dimitraki G, Papastefanakis E, Mastorodemos V, Repa A, Gergianaki I, Bertsias G, Sidiropoulos P, Simos P. Patient and partner dispositional optimism as a long-term predictor of illness representations in autoimmune diseases. J Health Psychol. 2017 Nov;22(13):1691-1700. doi: 10.1177/1359105316633287. Epub 2016 Mar 8. PMID: 26962131

66. Dimopoulou D, Trachana M, Pratsidou-Gertsi P, Sidiropoulos P, Kanakoudi-Tsakalidou F, Dimitroulas T, Garyfallos A. Predictors and long-term outcome in Greek adults with juvenile idiopathic arthritis: a 17-year continuous follow-up study. Rheumatology (Oxford). 2017 Nov 1;56(11):1928-1938. doi: 10.1093/rheumatology/kex265. PMID: 29088453.

67. Sfikakis PP, Bournia VK, Sidiropoulos P, Boumpas DT, Drosos AA, Kitas GD, Konstantonis G, Liossis SN, Manoussakis MN, Sakkas L, Tektonidou M, Tzioufas AG, Vlachoyiannopoulos PG, Kani C, Paterakis P, Litsa P, Vassilopoulos D. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. Clin Exp Rheumatol. 2017 Jul-Aug;35(4):579-585. Epub 2017 Mar 3. PMID: 28281458.

68. Latsoudis H, Mashreghi MF, Grün JR, Chang HD, Stuhlmüller B, Repa A, Gergiannaki I, Kabouraki E, Vlachos GS, Häupl T, Radbruch A, Sidiropoulos P, Doukoumetzidis K, Kardassis D, Niewold TB, Boumpas DT, Goulielmos GN. Differential Expression of miR-4520a Associated With Pyrin Mutations in Familial Mediterranean Fever (FMF). J Cell Physiol. 2017 Jun;232(6):1326-1336. doi: 10.1002/jcp.25602. Epub 2016 Dec 20. PMID: 27636101.

69. Myrthianou E, Zervou MI, Budu-Aggrey A, Eliopoulos E, Kardassis D, Boumpas DT, Kougkas N, Barton A, Sidiropoulos P, Goulielmos GN. Investigation of the genetic overlap between rheumatoid arthritis and psoriatic arthritis in a Greek population. Scand J Rheumatol. 2017 May;46(3):180-186. doi: 10.1080/03009742.2016.1199734. Epub 2016 Jul 20. PMID: 27440135.

70. Detorakis EE, Magkanas E, Lasithiotaki I, Sidiropoulos P, Boumpas DT, Gourtsoyiannis N, Antoniou K, Raissaki M. Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-α agents. Clin Exp Rheumatol. 2017 Jan-Feb;35(1):43-52. Epub 2016 Oct 27. PMID: 27908307.

71. Boubouchairopoulou N, Flouri I, Drosos AA, Boki K, Settas L, Zisopoulos D, Skopouli FN, Papadopoulos I, Iliopoulos A, Kyriopoulos J, Boumpas DT, Athanasakis K, Sidiropoulos P. Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status. Clin Exp Rheumatol. 2016 Nov-Dec;34(6):999-1005. Epub 2016 Oct 7. PMID: 27749220.

72. Papadaki G, Kambas K, Choulaki C, Vlachou K, Drakos E, Bertsias G, Ritis K, Boumpas DT, Thompson PR, Verginis P, Sidiropoulos P. Neutrophil extracellular traps exacerbate Th1-mediated autoimmune responses in rheumatoid arthritis by promoting DC maturation. Eur J Immunol. 2016 Nov;46(11):2542-2554. doi: 10.1002/eji.201646542. Epub 2016 Oct 5. PMID: 27585946.

73. Bertsias G, Karampli E, Sidiropoulos P, Gergianaki I, Drosos A, Sakkas L, Garyfallos A, Tzioufas A, Vassilopoulos D, Tsalapaki C, Sfikakis P, Panopoulos S, Athanasakis K, Perna A, Psomali D, Kyriopoulos J, Boumpas D. Clinical and financial burden of active lupus in Greece: a nationwide study. Lupus. 2016 Oct;25(12):1385-94. doi: 10.1177/0961203316642310. Epub 2016 Apr 6. PMID: 27055520.

74. Fanouriakis A, Pamfil C, Rednic S, Sidiropoulos P, Bertsias G, Boumpas DT. Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. Clin Exp Rheumatol. 2016 Sep-Oct;34(5):910-917. Epub 2016 Jul 26. PMID: 27463840.

75. Simos P, Ktistaki G, Dimitraki G, Papastefanakis E, Kougkas N, Fanouriakis A, Gergianaki I, Bertsias G, Sidiropoulos P, Karademas EC. Cognitive deficits early in the course of rheumatoid arthritis. J Clin Exp Neuropsychol. 2016 Sep;38(7):820-9. doi: 10.1080/13803395.2016.1167173. Epub 2016 May 1. PMID: 27133019.

76. Fanouriakis A, Pamfil C, Sidiropoulos P, Damian L, Flestea A, Gusetu G, Rednic S, Bertsias G, Boumpas DT. Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. Lupus. 2016 May;25(6):627-36. doi: 10.1177/0961203315622821. Epub 2015 Dec 21. PMID: 26692040.

77. Lasithiotaki I, Giannarakis I, Tsitoura E, Samara KD, Margaritopoulos GA, Choulaki C, Vasarmidi E, Tzanakis N, Voloudaki A, Sidiropoulos P, Siafakas NM, Antoniou KM. NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung. Eur Respir J. 2016 Mar;47(3):910-8. doi:10.1183/13993003.00564-2015. Epub 2016 Jan 7. PMID: 26743485.

78. Vlachou K, Mintzas K, Glymenaki M, Ioannou M, Papadaki G, Bertsias GK, Sidiropoulos P, Boumpas DT, Verginis P. Elimination of Granulocytic Myeloid-Derived Suppressor Cells in Lupus-Prone Mice Linked to Reactive Oxygen Species-Dependent Extracellular Trap Formation. Arthritis Rheumatol. 2016 Feb;68(2):449-61. doi: 10.1002/art.39441. PMID: 26414650.

79. Karademas EC, Ktistaki G, Dimitraki G, Papastefanakis E, Kougkas N, Fanouriakis A, Gergianaki I, Bertsias G, Sidiropoulos P, Simos P. Adaptation to an autoimmune disorder: Does mental flexibility impact illness-related selfregulation? Psychol Health. 2016;31(3):276-91. doi: 10.1080/08870446.2015.1083568. Epub 2015 Sep 14. PMID: 26286095

80. Choulaki C, Papadaki G, Repa A, Kampouraki E, Kambas K, Ritis K, Bertsias G, Boumpas DT, Sidiropoulos P. Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritis. Arthritis Res Ther. 2015 Sep 19;17:257. doi: 10.1186/s13075-015-0775-2.PMID: 26385789.

81. Repa A, Bertsias GK, Petraki E, Choulaki C, Vassou D, Kambas K, Boumpas DT, Goulielmos G, Sidiropoulos P. Dysregulated production of interleukin-1β upon activation of the NLRP3 inflammasome in patients with familial Mediterranean fever. Hum Immunol. 2015 Jul;76(7):488-95. doi:10.1016/j.humimm.2015.06.007. Epub 2015 Jun 12. PMID: 26074413.

82. Pamfil C, Fanouriakis A, Damian L, Rinzis M, Sidiropoulos P, Tsivgoulis G, Rednic S, Bertsias G, Boumpas DT. EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. Rheumatology (Oxford). 2015 Jul;54(7):1270-8. doi: 10.1093/rheumatology/keu482. Epub 2015 Jan 30. PMID: 25638807.

83. Putrik P, Ramiro S, Kvien TK, Sokka T, Uhlig T, Boonen A; Equity in Clinical Eligibility Criteria for RA treatment Working Group. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth? Ann Rheum Dis. 2014 Nov;73(11):2010-21. doi: 10.1136/annrheumdis-2013-203819. Epub 2013 Aug 12. PMID: 23940213

84. Kambas K, Chrysanthopoulou A, Vassilopoulos D, Apostolidou E, Skendros P, Girod A, Arelaki S, Froudarakis M, Nakopoulou L, Giatromanolaki A, Sidiropoulos P, Koffa M, Boumpas DT, Ritis K, Mitroulis I. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann Rheum Dis. 2014 Oct;73(10):1854-63.

85. Fanouriakis A, Mastorodemos V, Pamfil C, Papadaki E, Sidiropoulos P, Plaitakis A, Amoiridis G, Bertsias G, Boumpas DT. Coexistence of systemic lupus erythematosus and multiple sclerosis: Prevalence, clinical characteristics, and natural history. Semin Arthritis Rheum. 2014 Jun;43(6):751-8.

86. Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014 Feb;43(4):447-57.

87. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, Boonen A; Working Group «Equity in access to treatment of rheumatoid arthritis in Europe». Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014 Jan;73(1):198-206.

88. Souliotis K, Papageorgiou M, Politi A, Ioakeimidis D, Sidiropoulos P. Barriers to accessing biologic treatment for rheumatoid arthritis in Greece: the unseen impact of the fiscal crisis–the Health Outcomes Patient Environment (HOPE) study. Rheumatol Int. 2014 Jan;34(1):25-33. doi: 10.1007/s00296-013-2866-1.

89. Zervou MI, Myrthianou E, Flouri I, Plant D, Chlouverakis G, Castro-Giner F, Rapsomaniki P, Barton A, Boumpas DT, Sidiropoulos P, Goulielmos GN. Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population. PLoS One. 2013 Sep 10;8(9).

90. Kyrmizi I, Gresnigt MS, Akoumianaki T, Samonis G, Sidiropoulos P, Boumpas D, Netea MG, van de Veerdonk FL, Kontoyiannis DP, Chamilos G. Corticosteroids block autophagy protein recruitment in Aspergillus fumigatus phagosomes via targeting dectin-1/Syk kinase signaling. J Immunol. 2013 Aug 1;191(3):1287-99

91. Cobb JE, Plant D, Flynn E, Tadjeddine M, Dieudé P, Cornélis F, Ärlestig L, Dahlqvist SR, Goulielmos G, Boumpas DT, Sidiropoulos P, Krintel SB, Ørnbjerg LM, Hetland ML, Klareskog L, Haeupl T, Filer A, Buckley CD, Raza K, Witte T, Schmidt RE, FitzGerald O, Veale D, Eyre S, Worthington J. Identification of the tyrosine-protein phosphatase non-receptor type 2 as a rheumatoid arthritis susceptibility locus in europeans. PLoS One. 2013 Jun 20;8(6):e66456. doi: 10.1371/journal.pone.0066456.

92. Vazgiourakis VM, Zervou MI, Eliopoulos E, Sharma S, Sidiropoulos P, Franek BS, Myrthianou E, Melissourgaki M, Niewold TB, Boumpas DT, Goulielmos GN. Implication of VEGFR2 in systemic lupus erythematosus: a combined genetic and structural biological approach. Clin Exp Rheumatol. 2013 Jan-Feb;31(1):97-102.

93. Nakou M, Papadimitraki ED, Fanouriakis A, Bertsias GK, Choulaki C, Goulidaki N, Sidiropoulos P, Boumpas DT.Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to generation of plasma B cells. Clin Exp Rheumatol. 2013 Mar-Apr;31(2):172-9 (49)

94. Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, Kardassis D, Boumpas DT, Sidiropoulos PI. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012 Jun 12;14(3):R141

95. Vazgiourakis VM, Zervou MI, Choulaki C, Bertsias G, Melissourgaki M, Yilmaz N, Sidiropoulos P, Plant D, Trouw LA, Toes RE, Kardassis D, Yavuz S, Boumpas DT, Goulielmos GN. A common SNP in the CD40 region is associated with systemic lupus erythematosus and correlates with altered CD40 expression: implications for the pathogenesis. Ann Rheum Dis. 2011 Dec;70(12):2184-90

96. Raza K, Stack R, Kumar K, Filer A, Detert J, Bastian H, Burmester GR, Sidiropoulos P, Kteniadaki E, Repa A, Saxne T, Turesson C, Mann H, Vencovsky J, Catrina A, Chatzidionysiou A, Hensvold A, Rantapää-Dahlqvist S, Binder A, Machold K, Kwiakowska B, Ciurea A, Tamborrini G, Kyburz D, Buckley CD. Delays in assessment of patients with rheumatoid arthritis: variations across Europe. Ann Rheum Dis. 2011 Oct;70(10):1822-5

97. Eliopoulos E, Zervou MI, Andreou A, Dimopoulou K, Cosmidis N, Voloudakis G, Mysirlaki H, Vazgiourakis V, Sidiropoulos P, Niewold TB, Boumpas DT, Goulielmos GN. Association of the PTPN22 R620W polymorphism with increased risk for SLE in the genetically homogeneous population of Crete. Lupus. 2011 Apr;20(5):501-6.

98. Magkanas E, Detorakis E, Nikolakopoulos I, Gourtsoyianni S, Linardakis M, Sidiropoulos P, Boumpas D, Gourtsoyiannis N. Air trapping in Wegener’s granulomatosis: an additional finding on expiratory chest HRCT. Radiol Med. 2011 Sep;116(6):858-67

99. Goulielmos GN, Petraki E, Vassou D, Eliopoulos E, Iliopoulos D, Sidiropoulos P, Aksentijevich I, Kardassis D, Boumpas DT. The role of the pro-apoptotic protein Siva in the pathogenesis of Familial Mediterranean fever: A structural and functional analysis. Biochem Biophys Res Commun. 2010 Nov 5;402(1):141-6

100. Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, Klareskog L, Catrina AI, Sidiropoulos P, Boumpas DT. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010 Jul;62(7):1870-80

101. Plant D, Flynn E, Mbarek H, Dieudé P, Cornelis F, Arlestig L, Dahlqvist SR, Goulielmos G, Boumpas DT, Sidiropoulos P, Johansen JS, Ornbjerg LM, Hetland ML, Klareskog L, Filer A, Buckley CD, Raza K, Witte T, Schmidt RE, Worthington J. Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. Ann Rheum Dis. 2010 Aug;69(8):1548-53

102. Raptopoulou A, Linardakis C, Sidiropoulos P, Kritikos HD, Boumpas DT. Pulse cyclophosphamide treatment for severe refractory cutaneous lupus erythematosus. Lupus. 2010;19(6):744-7

103. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010 Feb;69(2):325-31.

104. Zervou MI, Castro-Giner F, Sidiropoulos P, Boumpas DT, Tosca AD, Krueger-Krasagakis The protein tyrosine phosphatase, non-receptor type 22 R620W polymorphism does not confer susceptibility to psoriasis in the genetic homogeneous population of Crete. Genet Test Mol Biomarkers. 2010 Feb;14(1):107-11

105. Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, Koutala H, Papadaki HA, Kritikos H, Boumpas DT. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11(4):R131
* Both authors contributed equally

106. Papadakis J, Sidiropoulos PI, Karvounaris S, Vrentzos G, Spanakis E, Ganotakis E, Kritikos H, Mikhailidis D, Boumpas DT. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis. Clinical & Experimental Rheumatology. 2009 Mar-Apr;27(2):292-8
* Both authors contributed equally

107. Pyrovolaki K, Mavroudi I, Sidiropoulos P, Eliopoulos AG, Boumpas DT, Papadaki HA. Increased expression of CD40 on bone marrow CD34+ hematopoietic progenitor cells in patients with systemic lupus erythematosus: Contribution to Fas-mediated apoptosis. Arthritis Rheum. 2009 Jan 29;60(2):543-552

108. Bertsias G, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos G, Kritikos H, Sidiropoulos P, Tzardi M, Kardassis D, Mamalaki C, Boumpas DT. Genetic, immunologic, and immunohistochemical analysis of the PD-1/PD-L1 pathway in human systemic lupus erythematosus. Arthritis & Rheum. 2009 Jan;60(1):207-18

109. Sidiropoulos P, Siakka P, Pagonidis K, Raptopoulou A, Kritikos H, Tsetis D, Boumpas DT. Sustained Improvement of Vascular Endothelial Function and Stable Carotid Artery Intima-Media Thickness Following a Long-Course of anti-TNFα Treatment in Rheumatoid Arthritis Patients. Scandinavian Journal of Rheumatology 2009 Jan-Feb;38(1):6-10

110. Zervou M, Sidiropoulos P, Petraki E, Vazgiourakis V, Krasoudaki E, Raptopoulou A, Kritikos H, Choustoulaki E, Boumpas DT and Goulielmos GN. Association of a TRAF1 and a STAT4 gene polymorphism with increased risk for rheumatoid arthritis in a genetically homogeneous population. Human Immunology 2008 Sep;69(9):567-71

111. Nakou M, Knowlton N, Papadaki E, Raptopoulou A, Sidiropoulos P, Kritikos H, Tassiulas I, Centola M, Boumpas DT. Gene expression in the bone marrow vs peripheral blood in human systemic lupus erythematosus: bone marrow better differentiates active from inactive patients and displays apoptosis and granulopoiesis signature. Arthritis & Rheum 2008 Nov;58(11):3541-9.

112. Raptopoulou A*, Sidiropoulos P*, Siakka P, Boki K, Drosos A, Aslanidis S, Karras D, Pikazis D, Vassilopoulos D, Karassa F, Boumpas DT. Evidence-based Recommendations for the Management of Ankylosing Spondylitis: Results of the Hellenic Working Group of the 3E Initiative in Rheumatology. Clin Exp Rheum 2008 Sep-Oct;26(5):784-92.
* Both authors contributed equally

113. Fragouli E, Eliopoulos E, Petraki E, Sidiropoulos P, Aksentijevich I, Galanakis E, Kritikos H, Repa A, Fragiadakis G, Boumpas DT, Goulielmos GN. Familial Mediterranean Fever (FMF) in Crete: a genetic and structural biological approach in a population of intermediate risk. Clin Genet. 2008 Feb;73(2):152-9.

114. Sidiropoulos P, Hatemi G, Song IH, Avouac J, Collantes E, Hamuryudan V, Herold M, Kvien TK, Mielants H, Mendoza HM, Olivieri I, Østergaard M, Schachna L, Sieper J, Boumpas DT, Dougados M. Evidence-based recommendations for the management of Ankylosing Spondylitis: Systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practicing rheumatologists. Rheumatology (Oxford). 2008 Mar;47(3):355-61

115. Vazgiourakis V, Sidiropoulos P, Bertsias G, Koutsounaki E, Fragouli E, Raptopoulou A, Kritikos H, Boumpas DT, Goulielmos GN. Association of the nitric oxide synthase (eNOS) gene polymorphism with increased risk for both lupus glomerulonephritis and rheumatoid arthritis in a single genetically homogeneous population. Lupus. 2007;16(11):867-74.

116. Kastrinaki MC, Sidiropoulos P, Roche S, Ringe J, Lehmann S, Kritikos H, Vlahava VM, Delorme B, Eliopoulos G, Jorgensen C, Charbord P, Häupl T, Boumpas DT, Papadaki HA. Functional, molecular and proteomic characterization of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis. 2008 Jun;67(6):741-9

117. Karvounaris SA*, Sidiropoulos PI*, Papadakis JA, Spanakis EK, Bertsias GK, Kritikos HD, Ganotakis ES, Boumpas DT. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis. 2007;66(1):28-33
* Both authors contributed equally

118. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I, Raptopoulou A, Kritikos HD, Mamalaki C, Sidiropoulos P, Boumpas DT. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum. 2006;54(11):3601-11

119. Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol. 2006 Dec;33(12):2440-6
* Both authors contributed equally

120. Goulielmos GN, Fragouli E, Aksentijevich I, Sidiropoulos P, Boumpas DT, Eliopoulos E. Mutational analysis of the PRYSPRY domain of pyrin and implications for familial mediterranean fever (FMF). Biochem Biophys Res Commun. 2006 Jul 14;345(4):1326-32

121. Giaglis S, Mimidis K, Papadopoulos V, Thomopoulos K, Sidiropoulos P, Rafail S, Nikolopoulou V, Fragouli E, Kartalis G, Tzioufas A, Boumpas D, Ritis K. Increased frequency of mutations in the gene responsible for familial Mediterranean fever (MEFV) in a cohort of patients with ulcerative colitis: evidence for a potential disease-modifying effect? Dig Dis Sci. 2006;51(4):687-92

122. Sidiropoulos PI, Siakka P, Raptopoulou A, Mamoulaki M, Choulaki C, Koutala H, Kouroumali H, Kritikos H, Boumpas DT. An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of ciclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab. Ann Rheum Dis. 2006;65(4):538-41

123. Sidiropoulos P, Kritikos HD, Siakka P, Mamoulaki M, Kouroumali H, Voudouris K, Boumpas DT. Low dose of infliximab is inadequate in most patients with spondylarthropathies. Clin Exp Rheumatol. 2005;23(4):513-6

124. Sidiropoulos P, Bertsias G, Kritikos HD, Kouroumali H, Voudouris K, Boumpas DT. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis. 2004;63(2):144-8

125. Voudouris KP, Sidiropoulos P, Vounotripidis P, Arvanitakis M. Enthesial fibrocartilage – bone interaction: a radiographic study of selected sites of nonsynovial peripheral enthesopathy. J Musculoskelet Neuronal Interact. 2003;3(1):89-100

126. Sidiropoulos P, Liu H, Mungre S, Anderson L, Thimmapaya B, Pope RM. Efficacy of adenoviral TNF alpha antisense is enhanced by a macrophage specific promoter. Gene Ther. 2001;8(3):223-31

127. Liu H, Sidiropoulos P, Song G, Pagliari LJ, Birrer MJ, Stein B, Anrather J, Pope RM. TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta. J Immunol. 2000; 164(8):4277-85

HELLENIC ASSOCIATION OF RHEUMATOLOGISTS